

บรรณานุกรม

- ชลธิป พงศ์สกุล. ภาวะติดเชื้อทางเดินปัสสาวะ. ใน: กาญจนา จันทร์สูง, จิตติมา ศิริจิระชัย และ พิศาล ไม้เรียง, บรรณาธิการ. Short Note in Medicine. ขอนแก่น: คลังนาวิทยา, 2543: 238-242.
- ทัตสนี นุชประยูร และเดิมศรี ชำนิจารกิจ. สถิติในวิจัยทางการแพทย์. กรุงเทพมหานคร : จุฬาลงกรณ์มหาวิทยาลัย, 2541.
- พรรณพิศ สุวรรณกุล. แนวทางการรักษาภาวะติดเชื้อในทางเดินปัสสาวะ. ใน: วิทยา ศรีดามา, บรรณาธิการ. Clinical Practice Guideline ทางอายุรกรรม พ.ศ. 2544. กรุงเทพมหานคร : จุฬาลงกรณ์มหาวิทยาลัย, 2544: 295-308.
- โสภณ นภาพร. การติดเชื้อทางเดินปัสสาวะ ใน: วิทยา ศรีดามา, บรรณาธิการ. ตำราอายุรศาสตร์ 2. กรุงเทพมหานคร : ยูนิตีส์พับเลชัน, 2541: 237-266.
- อโนชา อุทัยพัฒน์ และนงลักษณ์ สุขวานิชย์ศิลป์. เกสซ์วิทยา เล่ม 2. กรุงเทพมหานคร : นิเวศมิตรการพิมพ์, 2543. 175-178.
- Aguiar JM., Chacon J., Conton R. and Baquero F. The emergence of highly fluoroquinolone-resistant *Escherichia coli* in community-acquired urinary tract infections. J Antimicrob Chemother. 2001 ; 47 : 349-350.
- Aguilar L., Balcabao IP., Salva P., Martin M., Costa J., Prieto J., et al. Ex vivo antibacterial properties of rifloxacin compared with those of norfloxacin in a study with healthy volunteers. Antimicrob Agents Chemother. 1996 ; 40 :17-21.
- Boy D., Well M., Kinzig-Schippers M., Sorgel F., Ankel-Fuchs D. and Naber KG. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 milligrams) versus ciprofloxacin (500 milligrams) in healthy volunteers after a single oral dose. Int J Antimicrob Agents. 2004 ; 23S1 : S6-S16.
- Brown PD., Freeman A. and Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among *Escherichia coli* isolates in Michigan. CID. 2002 ; 34 : 1061-1066.
- Cizman M., Orazem A., Krizan-Hergouth V. and Kolman J. Correlation between increased consumption of fluoroquinolones in outpatients and resistance of *Escherichia coli* from urinary tract infections. J Antimicrob Chemother. 2001 ; 47 : 502.

- Crump B., Wise R., Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. *Antimicrob Agents Chemother.* 1983 ; 24 :784-786.
- Ena J., Amador C., Carmen M. and Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant *Escherichia coli*. *J Urol.* 1995 ; 153 : 117-120.
- Garua J., Xercavins M., Rodriguez-carballeira M., Gomez-vera JR., Coll I., Vidal D., et al. Emergence and dissemination of quinilone- resistant *Escherichia coli* in the community. *Antimicrob Agents Chemother.* 1999 ; 43 : 2736-2741.
- Goettsch W., Pelt W.V., Nagelkerke N., Hendrix MGR., Buiting AGM., Petit PL., et al. Increasing resistance to fluoroquinolones in *Escherichia coli* from urinary tract infections in The Netherlands. *J Antimicrob Chemother.* 2000 ; 46 : 223-228.
- Henry D., Ellison W., Sullivan J., Mansfield DL., Magner DJ., Dorr MB., et al. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin . *Antimicrob Agents Chemother.* 1998 ; 42 : 2262-2266.
- Hooton TM., Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. *Int J Antimicrob Agents.* 2003 ; 22 (1 Suppl) : 65-72.
- Hooton TM., Scholes D., Gupta K., Stapleton AE., Roberts PL. and Stamm WE. Amoxicillin – clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women. *JAMA.* 2005 ; 293 : 949-955.
- Kahlmeter G. The ECO-SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens- interim report. *J Antimicrob Chemother.* 2000 ; 46 (1 Suppl) : 15-22.
- Kahlmeter G., Menday P. and Cars O. Non-hospital antimicrobial usage and resistance in community- acquired *Escherichia coli* urinary tract infection. *J Antimicrob Chemother.* 2003 ; 49 : 1-6.
- Karlowsky JA., Kelly LJ., Thornsberry C., Jones ME. and Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of *Escherichia coli* from female outpatients in The United States. *Antimicrob Agents Chemother.* 2002 ; 40 : 2540-2545.
- Kunin CM. Urinary tract infection in females. *CID.* 1994 ; 18 : 1-12.

- Lindgren PK., Karlsson A. and Hughes D. Mutation rate and evolution of fluoroquinolone resistance in *Escherichia coli* isolates from patients with urinary tract infections. *Antimicrob Agents Chemother.* 2003 ; 47 : 3222-3232.
- Masterton RG and Bochler JA. High-dosage co-amoxiclavate in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. *J Antimicrob Chemother.* 1995 ; 35 : 129-137.
- Mazzulli T. Resistance trends in urinary tract pathogens and impact on management. *J Urol.* 2002 ; 1160 : 1720-1722.
- Mccarty JM., Richard G., Huck W., Turker RM., Tosiello RL., Shan M., et al. A randomized trial of short-course ciprofloxacin, ofloxacin or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. *Am J Med.* 1999 ; 106 : 292-299.
- Mcdonald LC., Chen FJ., Lo HJ., Yin HG., Lu PL., Huang CH., et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in *Escherichia coli* in Taiwan and contributions of distinct selective pressures. *Antimicrob Agents Chemother.* 2001 ; 45 : 3084-3091.
- Murray PR., Baron EJ., Pfaller MA., Tenover FC. and Tenover RH. *Manual of clinical microbiology.* 6th ed. Washington D.C. : Asm Press, 1995 ; 1327-41.
- Naber KG., Which fluoroquinolones are suitable for the treatment of urinary tract infections? *Int J Antimicrob Agents.* 2001 ; 17 : 331-341.
- National Antimicrobial Resistance Surveillance Center Thailand. Antimicrobial susceptibility. (on line) , 2000-2002. Available at : <http://www.dmsc.moph.go.th/webroot/ars/index.htm>.
- National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing ; Eleventh Informational Supplement. NCCLS document M100-S11. 2001 ; 21 : 46-47.
- Nicolle LE., Hoepelmam AI., Floor M., Verhoef J., Norgard K. Comparison of three days' therapy with cefcanel or amoxicillin for the treatment of acute uncomplicated urinary tract infection. *Scand J Infect Dis.* 1993 ; 25 : 631-637.

- Pei-Yuan X., Ping F., Li Z., Xiao-Ju L. and Bing-Ju L. Accumulation of ofloxacin and tosylfloxacin in fluoroquinolone-resistant *E. coli*. *Acta Pharmacol Sin.* 2001 ; 3 : 210-214.
- Raz R., Chazan B. and Kennes Y. Empiric use of TMP/SMX in the treatment of women with uncomplicated UTIs in geographical area with a high prevalence of TMP/SMX-resistant uropathogens. *CID.* 2002 ; 34 : 1165-1169.
- Richard GA., Mathew CP., Kirstein JM., Orchard D. and Yang JY. Single – dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women : results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. *Urology.* 2002 ; 59 : 334-339.
- Rubin RH., Shapiro ED., Andriole VT., Davis RJ. and Stamm WE. General guidelines for the evaluation of new anti-infective drugs for the treatment of urinary tract infection. *CID.* 1992 ; 15 (1 Suppl) : 216-227.
- Schlager TA., Hendley JO., Lohr JA., and Whittam TS. Effects of periurethral colonization on the risk of urinary tract infection in health girls after their first urinary tract infection. *Pediatr Infect Dis J.* 1993 ; 12 : 988-993.
- Swanson BN., Boppana VK., Vlasses PH., Rotmensch HH., Ferguson RK. Norfloxacin disposition after sequentially increasing oral doses. *Antimicrob Agents Chemother.* 1983 ; 23 :284-288.
- Velasco M., Horcajada JP., Mensa J., Moreno-Martinez A., Vila J., Martinez JA., et al. Decreased invasive capacity of quinolone-resistant *Escherichia coli* in patients with urinary tract infections. *CID.* 2001 ; 33 : 1682-1686.
- Wagenlehner FME., Wydra S., Onda H., Kinzig-Schippers M., Sorgel F. and Nager KG. Concentrations in plasma, urinary excretion and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. *Antimicrob Agents Chemother.* 2003 ; 47 :3789-3794.
- Warren JW., Abrutyn E., Hebel R., Johnson JR., Schaeffer AJ. And Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. *CID.* 1999 ; 29 : 745-758.

- Winstanley TG., Limb DI., Eggington R. and Hancock F. A 10 year survey of the antimicrobial susceptibility of urinary tract isolates in the UK : the Microb Base project. *J Antimicrob Chemother.* 1997 ; 40 : 591-594.
- Yoshida H., Bogaki M., Nakamura M. and Nakamura S. Quinolones resistance-determining region in the DNA gyrase *gyrA* gene of *Escherichia coli*. *Antimicrob Agents Chemother.* 1990 ; 34 : 1271-1272.
- Zeiler HJ., Beermann D., Wingender W., Froster D. and Schacht P. Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. *Infection* . 1988 ; 16 (1 Suppl) : 19-23.
- Zhanel GG., Karlowsky JA., Harding GK., Carrie A., Mazzulli T., Low DE., et al. A Canadian national surveillance study of urinary tract isolates from outpatients : comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin and ciprofloxacin. *Antimicrob Agents Chemother.* 2000 ; 44 : 1089-1092.